Myelodysplastic Syndrome Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia
Conditions: Myelodysplastic Syndromes; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Patient Preference Interventions: Drug: Subcutaneous azacitidine; Drug: Oral decitabine/cedazuridine Sponsor: Otsuka Australia Pharmaceutical Pty Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 1, 2023 Category: Research Source Type: clinical trials

FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS)
SAN FRANCISCO, May 05, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that MATTERHORN, a Phase 3 clinical study of roxadustat for treatment of anemia in patients with transfusion-dependent lower risk myelodysplastic syndromes... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 5, 2023 Category: Pharmaceuticals Source Type: clinical trials

A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)
Condition: Myelodysplastic Syndromes Interventions: Drug: Decitabine/Cedazuridine; Drug: Magrolimab Sponsor: Astex Pharmaceuticals, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 28, 2023 Category: Research Source Type: clinical trials